申请人:Mitsubishi Chemical Corporation
公开号:EP0608897A2
公开(公告)日:1994-08-03
Benzoylacrylamide derivatives of the formula (I):
wherein R1 and R2 each independently represent a hydrogen atom, C1 ~ C5 alkyl, C3 ~ C8 cycloalkyl optionally intervened by -NR8- (R8 represents phenyl or C1 ~ C5 alkyl which is unsubstituted or substituted with phenyl),
(n is an integer of 0 to 3 and X and Y each independently represent a hydrogen atom, a halogen atom, C1 ~ C5 alkyl or C1 ~ C5 alkoxy), -(CH2)m-A (m is an integer of 0 to 3 and A represents an optionally substitued heterocycle), -COR9 (R9 represents C1 ~ C5 alkyl which is unsubstituted or substituted with phenyl, phenyl which is unsubstituted or substituted with C1 ~ C5 alkyl or a halogen atom, or C1 ~ C5 alkoxy which is unsubstituted or substituted with phenyl) -SO2R10 (R10 represents C1 ~ C5 alkyl which is unsubstituted or substituted with phenyl or a halogen atom, or phenyl which is unsubstituted or substituted with C1 ~ C5 alkyl), or -OR11 (R11 represents a hydrogen atom, or C1 ~ C5 alkyl which is unsubstituted or substituted with phenyl); or when R1 and R2 are taken together, they represent C3 ~ C6 alkylene optionally intervened by -O- or -NR12- (R12 represents a hydrogen atom, phenyl or C1 ~ C5 alkyl); and R3, R4, R5, R6 and R7 each independently represent a hydrogen atom, a halogen atom, C1 ~ C5 alkyl which is unsubstituted or substituted with a halogen atom or -OR13 (R13 represents a hydrogen atom or C1 ~ C5 alkyl which is unsubstituted or substituted with a halogen atom or phenyl); or when their adjacent substituents are taken together, they represet C1 ~ C3 oxyalkylene having one or two oxygen atoms, and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing at least one of these compounds, which is useful as a tyrosine kinase inhibitor and useful for suppressing the growth of cnacer cells.
式 (I) 的苯甲酰丙烯酰胺衍生物:
其中 R1 和 R2 各自独立地代表氢原子、C1 ~ C5 烷基、C3 ~ C8 环烷基,可选地由 -NR8- 介入(R8 代表苯基或未取代或被苯基取代的 C1 ~ C5 烷基)、
(n为 0 至 3 的整数,X 和 Y 各自独立地代表氢原子、卤素原子、C1 ~ C5 烷基或 C1 ~ C5 烷氧基)、-(CH2)m-A(m 为 0 至 3 的整数,A 代表任选被取代的杂环)、-COR9(R9 代表未被取代或被苯基取代的 C1 ~ C5 烷基、未被取代或被 C1 ~ C5 烷基或卤素原子取代的苯基、或代表未被苯基取代或被苯基取代的 C1 ~ C5 烷氧基)-SO2R10(R10 代表未被苯基或卤素原子取代或被苯基取代的 C1 ~ C5 烷基,或代表未被 C1 ~ C5 烷基取代或被 C1 ~ C5 烷基取代的苯基),或-OR11(R11 代表氢原子,或代表未被苯基取代或被苯基取代的 C1 ~ C5 烷基);或当 R1 和 R2 合在一起时,它们代表 C3 ~ C6 亚烷基,中间可选择有 -O- 或 -NR12- (R12 代表氢原子、苯基或 C1 ~ C5 烷基);以及 R3、R4、R5、R6 和 R7 各自独立地代表氢原子、卤素原子、未被取代或被卤素原子取代的 C1 ~ C5 烷基或 -OR13 (R13 代表氢原子或未被取代或被卤素原子或苯基取代的 C1 ~ C5 烷基);或当它们的相邻取代基结合在一起时,它们代表具有一个或两个氧原子的 C1 ~ C3 氧亚烷基,及其药学上可接受的盐,以及含有至少一种这些化合物的药物组合物,可用作酪氨酸激酶抑制剂,并可用于抑制癌细胞的生长。